A decrease in platelet and neutrophil counts was seen during the VELCADE® dosing period (days 1 - 11) with a rapid return toward baseline during the rest period (days 12 - 21); platelet and neutrophil counts were lowest at day 11
–
For all patients, the mean platelet nadir was approximately 40% of baseline
–
The incidence of febrile neuropathy was less than 1% in both Phase 3 and Phase 2 trials
Consistent Platelet Kinetics Observed in APEX Trial with VELCADE1
Patient management and safety
–
Transfusions may be used at the discretion of the physician
–
The incidence of grade15 4 thrombocytopenia in APEX was 4%; 2% of patients discontinued VELCADE treatment due to thrombocytopenia of any grade
–
There have been reports of gastrointestinal and intracerebral hemorrhage in association with
thrombocytopenia as a result of VELCADE treatment
–
Platelet count should be monitored prior to each dose of VELCADE
Please click here to view additional important safety information.
For full Prescribing Information click here. (pdf) (74KB)
For further information about VELCADE® (bortezomib) for Injection, call 1-866-VELCADE (U.S. clinicians only).
